Diamedica Stock Analysis

DMAC -  USA Stock  

USD 8.20  0.17  2.12%

Diamedica Therapeutics price slip over the last few months could raise concerns from investors as the firm it trading at a share price of 8.20 on 49,744 in volume. The company executives were not very successful in positioning the firm resources to exploit market volatility in May. However, diversifying your holdings with Diamedica Therapeutics or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.24. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Diamedica Therapeutics partners.
Continue to Investing Opportunities.

Search Stock Analysis 

The Diamedica Therapeutics stock analysis report makes it easy to digest most publicly released information about Diamedica Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Diamedica stock analysis module also helps to analyze the Diamedica Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Diamedica Stock Analysis Notes

About 35.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.78. Diamedica Therapeutics had not issued any dividends in recent years. The entity had a split on the 15th of November 2018. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To learn more about Diamedica Therapeutics call Rick Pauls at 763 612 6755 or check out http://www.diamedica.com.

Diamedica Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Diamedica Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Diamedica Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Diamedica Therapeutics generates negative expected return over the last 90 days
Diamedica Therapeutics has high historical volatility and very poor performance
Diamedica Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 447.37 K. Net Loss for the year was (12.29 M) with profit before overhead, payroll, taxes, and interest of 500 K.
Diamedica Therapeutics currently holds about 27.51 M in cash with (9.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.47.
Diamedica Therapeutics has a frail financial position based on the latest SEC disclosures

Diamedica Therapeutics Upcoming and Recent Events

Earnings reports are used by Diamedica Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Diamedica Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of August 2021
Next Earnings Report3rd of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End9th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Diamedica Largest EPS Surprises

Earnings surprises can significantly impact Diamedica Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Diamedica Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Diamedica Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Diamedica Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Diamedica Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
5th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
29th of April 2021
Other Events
10th of March 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
12th of February 2021
Unclassified Corporate Event
23rd of December 2020
Unclassified Corporate Event
4th of November 2020
Financial Statements and Exhibits. Results of Operations and Financial Condition

Diamedica Therapeutics Thematic Classifications

In addition to having Diamedica Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Diamedica Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 168.32 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Diamedica Therapeutics's market, we take the total number of its shares issued and multiply it by Diamedica Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Diamedica Profitablity

Diamedica Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Diamedica Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Diamedica Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Diamedica Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Diamedica Therapeutics' profitability requires more research than a typical breakdown of Diamedica Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.57) (0.62) 
Return on Average Equity(0.61) (0.66) 
Return on Invested Capital(0.88) (0.91) 
Return on Sales(10.18) (10.98) 

Management Efficiency

The entity has return on total asset (ROA) of (42.73) % which means that it has lost $42.73 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (73.1) %, meaning that it created substantial loss on money invested by shareholders. Diamedica Therapeutics management efficiency ratios could be used to measure how well diamedica therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of June 17, 2021, Return on Average Assets is expected to decline to -0.62. In addition to that, Return on Average Equity is expected to decline to -0.66. Diamedica Therapeutics Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 28.09 Million. The current year Current Assets is expected to grow to about 30.1 M, whereas Asset Turnover is forecasted to decline to 0.0447.
Last ReportedProjected for 2021
Book Value per Share 1.66  1.44 
Enterprise Value over EBIT(15.00) (15.39) 
Enterprise Value over EBITDA(14.79) (15.18) 
Price to Book Value 7.30  7.12 
Tangible Assets Book Value per Share 1.79  1.59 
Enterprise Value180.3 M146.4 M
Tangible Asset Value28.1 M30.3 M

Technical Drivers

As of the 17th of June 2021, Diamedica Therapeutics shows the mean deviation of 3.07. Diamedica Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Diamedica Therapeutics, which can be compared to its rivals. Please confirm Diamedica Therapeutics mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and information ratio to decide if Diamedica Therapeutics is priced favorably, providing market reflects its regular price of 8.2 per share. Given that Diamedica Therapeutics has jensen alpha of (0.17), we urge you to verify Diamedica Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Diamedica Therapeutics Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Diamedica Therapeutics more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Diamedica Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Diamedica Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Diamedica Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Diamedica Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Diamedica Therapeutics Predictive Daily Indicators

Diamedica Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Diamedica Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Diamedica Therapeutics Forecast Models

Diamedica Therapeutics time-series forecasting models is one of many Diamedica Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Diamedica Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Diamedica Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Diamedica Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Diamedica shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Diamedica Therapeutics. By using and applying Diamedica Stock analysis, traders can create a robust methodology for identifying Diamedica entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(10.15) (10.95) 
Gross Margin 0.90  0.89 
Profit Margin(10.32) (11.14) 
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Current Diamedica Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Diamedica analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Diamedica analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
23.75Strong Buy4Odds
Diamedica Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Diamedica analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Diamedica stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Diamedica Therapeutics, talking to its executives and customers, or listening to Diamedica conference calls.
Diamedica Analyst Advice Details

Diamedica Stock Analysis Indicators

Diamedica Therapeutics stock analysis indicators help investors evaluate how Diamedica Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Diamedica Therapeutics shares will generate the highest return on investment. By understating and applying Diamedica Therapeutics stock analysis, traders can identify Diamedica Therapeutics position entry and exit signals to maximize returns.
Quick Ratio13.73
Fifty Two Week Low3.77
Shares Short Prior Month156.75k
Average Daily Volume Last 10 Day95.04k
Average Daily Volume In Three Month96.98k
Shares Percent Shares Out1.00%
Short Percent Of Float1.07%
Forward Price Earnings-6.01
Float Shares16.41M
Fifty Two Week High10.88
Enterprise Value To Ebitda-11.84
Fifty Day Average7.94
Two Hundred Day Average8.61
Continue to Investing Opportunities. Note that the Diamedica Therapeutics information on this page should be used as a complementary analysis to other Diamedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Diamedica Therapeutics Stock analysis

When running Diamedica Therapeutics stock analysis, check to measure Diamedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamedica Therapeutics is operating at the current time. Most of Diamedica Therapeutics' stock examination focuses on studying past and present price action to predict the probability of Diamedica Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Diamedica Therapeutics' price. Additionally, you may evaluate how the addition of Diamedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Search
Search for activelly-traded equities including funds and ETFs from over 30 global markets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
The market value of Diamedica Therapeutics is measured differently than its book value, which is the value of Diamedica that is recorded on the company's balance sheet. Investors also form their own opinion of Diamedica Therapeutics stock's value that differs from its market value or its book value, called intrinsic value, which is Diamedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Diamedica Therapeutics' market value can be influenced by many factors that don't directly affect Diamedica Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Diamedica Therapeutics' stock value and its price as these two are different measures arrived at by different means. Investors typically determine Diamedica Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Diamedica Therapeutics' stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.